An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals

Table 3

BEV treatment disposition.

Variable	Total (median, range)
Number of BEV cycles	123 (4, 1–16)
	Number of patients (%)
Patients treated at a dose of 5 mg/kg every 2 weeks	3* (15,8)
Patients treated at a dose of 10 mg/kg every 2 weeks	15* (78,9)
Patients treated at a dose of 15 mg/kg every 3 weeks	2 (10,5)

*One patient had a dose escalation from 5 to 10 mg/kg every 2 weeks after the first cycle.